BioSpace News Archive

DEA-approved micro-fulfillment pharmacy alleviates COVID-19 health risk of waiting in line at crowded pharmacies, speeds time-to-treatment

Operations Management Veteran Robert Sullivan Brings Over 30 Years of Experience to Bio-Pharmaceutical Startup

Caris’ AI-powered predictor helps gauge which metastatic colorectal cancer patients will benefit from treatment with current standard of care regimen Exploratory analyses also found benefit in advanced esophageal/gastro-esophageal junction cancers and pancreatic ductal adenocarcinoma

LGC Maine Standards¹ announces the release of VALIDATE ® PTH to meet the linearity and calibration verification needs of clinical laboratories running the Roche cobas ® platform. The product (Order No. 303RO), which includes the analyte, Parathyroid Hormone, is formulated in a human serum matrix, using the CLSI EP06-A

Skinopathy, a new Canadian medical technology start-up, is developing Artificial Intelligence technology to help fight the scourge of skin cancer.

Cerevance, a private drug discovery and development company focused on brain diseases, today announced the appointment of David Lubner, a senior finance executive with more than 25 years of experience in the life sciences industry, to Cerevance’s Board of Directors. Mr. Lubner most recently served as executive vice president and chief financial officer of Ra Pharma, which was acquired by UCB in April of this year. Before joining Ra Pharma, he served

- At 24 weeks, asciminib nearly doubled the major molecular response (MMR) rate compared to Bosulif® (bosutinib)*, in patients resistant to, or intolerant of, at least two prior tyrosine kinase inhibitor (TKI) therapies1 - Despite advances in chronic myeloid leukemia (CML) care, many patients are at risk of disease progression, and sequential TKI therapy may be associated with increased resistance and intolerance2-7 - Data further reinforce the potential of asciminib to help

Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it has submitted its application for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for the company’s SARS-CoV-2 molecular diagnostic test on the Revogene ® platform. The SARS-CoV-2 test is a molecular diagnostic test for the qualitative detection of the SARS-CoV-2 virus, the

Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced today the completion of multiple surgeries with the 8mm PROLIFT Expandable System.

Leaders and clinical improvers gather virtually to share new ideas and evidence-based approaches to improve population health and health equity